Search
Home
Latest
News
North America
Europe
Asia
Middle East
Global
Coins2Day 500
Coins2Day 500 U.S.
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Great Place To Work
Analytics
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
Home
Latest
Latest
News
North America
Europe
Asia
Middle East
Global
Coins2Day 500
Coins2Day 500
Coins2Day 500 U.S.
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Finance
Finance
Economy
Banking
Personal Finance
Investing
Real Estate
Energy
Crypto
Tech
Tech
Big Tech
Startups & Venture
AI
Innovation
Cybersecurity
Leadership
Leadership
Future Of Work
Success
C-Suite
Workplace Culture
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Health
Travel & Leisure
Education
Rankings
Rankings
Great Place To Work
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Press Releases
Video
Podcasts
home
home
Ozempic
Ozempic
Success
The wealthy 1% are turning to new status symbols that can’t be bought—and it’s hurting Dior, Versace, and Burberry
By
Emma Burleigh
December 3, 2025
Health
Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic
By
Nick Lichtenberg
November 6, 2025
C-Suite
Ray Dalio is backing a $1 billion blueberry unicorn that sells berries nearly the size of golf balls
By
Eva Roytburg
November 4, 2025
Health
Adult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
By
Matty Merritt
and
Morning Brew
October 31, 2025
Health
Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients
By
Nick Lichtenberg
August 18, 2025
Commentary
Trump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud
By
Ari Yampolsky
and
Max Voldman
August 12, 2025
Newsletters
Exclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers
By
Emma Hinchliffe
August 7, 2025
C-Suite
Novo Nordisk selects insider Maziar Mike Doustdar as new CEO, to tackle ‘recent market challenges’
By
AFP
July 29, 2025
Finance
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
By
Jason Ma
June 17, 2025
Finance
Editorial Team
By
Naomi Kresge
and
Bloomberg
May 16, 2025
Health
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
By
Ryan Hogg
May 9, 2025
Retail
Novo Nordisk slides on pressure from Lilly’s pill study
By
Marthe Fourcade
and
Bloomberg
April 22, 2025
Magazine
Ozempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?
By
Vivienne Walt
March 31, 2025
Finance
Novo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
By
Chris Morris
March 7, 2025
Commentary
The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up
By
Wendy Barnes
March 4, 2025
Most Popular
Success
Despite his $2.6 billion net worth, MrBeast says he’s having to borrow cash and doesn’t even have enough money in his...
By
Emma Burleigh
AI
'Godfather of AI' says the technology will create massive unemployment and send profits soaring — 'that is the...
By
Jason Ma
Tech
Elon Musk asked people to upload their medical data to X so his AI company could learn to interpret MRIs and CT scans
By
Sasha Rogelberg